Clinical efficacy of neoadjuvant chemotherapy combined with PD-1 inhibitor in the treatment of triple negative breast cancer

doi:10.11958/20221554

Abstract

Abstract:

Objective To investigate the clinical efficacy of neoadjuvant chemotherapy combined with PD-1 inhibitor in the treatment of triple negative breast cancer and its effect on immune function. Methods Eighty patients with triple negative breast cancer were randomly divided into the control group and the observation group, with 40 cases in each group. The control group received sequential chemotherapy of doxorubicin liposome + cyclophosphamide + albumin paclitaxel (AC-T), and the observation group was treated with PD-1 inhibitor on the basis of the control group. The quality of life, clinical efficacy, operation time, intraoperative blood loss, immune function and adverse reactions were compared between the two groups. Results After treatment, the SF-36 score was significantly higher in the observation group (84.55±6.09) than that of the control group (75.93±6.12, P<0.05). After 8 courses of treatment, the complete response rate (CRR), CD4⁺, CD8⁺, CD4⁺/CD8⁺, immunoglobulin IgG, IgA and IgM levels were significantly better in the observation group than those in the control group (P<0.05). The operative time [(43.25±6.85) min vs. (82.53±8.53) min] and intraoperative bleeding [(136.52±8.74) mL vs. (241.63±8.32) mL] were significantly decreased in the observation group than those of the control group (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion Neoadjuvant chemotherapy combined with PD-1 inhibitor in the treatment of triple negative breast cancer can improve the immune function and quality of life of patients, and ensure the safety of clinical treatment.

Key words: immune checkpoint inhibitors, chemoradiotherapy, adjuvant, triple negative breast neoplasms, quality of life, immunity, active

CLC Number:

R737.9

Figures/Tables 5

References 19

[1]	YIN L, DUAN J J, BIAN X W, et al. Triple-negative breast cancer molecular subtyping and treatment progress[J]. Breast Cancer Res, 2020, 22(1):61. doi:10.1186/s13058-020-01296-5.
[2]	KWAPISZ D. Pembrolizumab and atezolizumab in triple-negative breast cancer[J]. Cancer Immunol Immunother, 2021, 70(3):607-617. doi:10.1007/s00262-020-02736-z.
[3]	WON K A, SPRUCK C. Triple-negative breast cancer therapy:current and future perspectives (Review)[J]. Int J Oncol, 2020, 57(6):1245-1261. doi:10.3892/ijo.2020.5135.
[4]	LEON-FERRE R A, HIEKEN T J, BOUGHRY J C. The landmark series:neoadjuvant chemotherapy for triple-negative and HER2-positive breast cancer[J]. Ann Surg Oncol, 2021, 28(4):2111-2119. doi:10.1245/s10434-020-09480-9.
[5]	KEENAN T E, TOLANEY S M. Role of immunotherapy in triple-negative breast cancer[J]. J Natl Compr Canc Netw, 2020, 18(4):479-489. doi:10.6004/jnccn.2020.7554.
[6]	EMENS L A. Breast cancer immunotherapy:facts and hopes[J]. Clin Cancer Res, 2018, 24(3):511-520. doi:10.1158/1078-0432.CCR-16-3001.
[7]	BERGIN A R T, LOI S. Triple-negative breast cancer:recent treatment advances[J]. F1000Res, 2019, 8:F1000 Faculty Rev-1342. doi:10.12688/f1000research.18888.1.
[8]	LYONS T. Targeted therapies for triple-negative breast cancer[J]. Curr Treat Options Oncol, 2019, 20(11):82. doi:10.1007/s11864-019-0682-x.
[9]	ZHU Y, ZHU X, TANG C, et al. Progress and challenges of immunotherapy in triple-negative breast cancer[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188593. doi:10.1016/j.bbcan.2021.188593.
[10]	MARRA A, CURIGLIANO G. Adjuvant and neoadjuvant treatment of triple-negative breast cancer with chemotherapy[J]. Cancer J, 2021, 27(1):41-49. doi:10.1097/PPO.0000000000000498.
[11]	NEDELJKOVIĆ M, DAMJANOVIĆ A. Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge[J]. Cells, 2019, 8(9):957. doi:10.3390/cells8090957.
[12]	GARRIDO-CASTRO A C, LIN N U, POLYAK K. Insights into molecular classifications of triple-negative breast cancer:improving patient selection for treatment[J]. Cancer Discov, 2019, 9(2):176-198. doi:10.1158/2159-8290.CD-18-1177.
[13]	TARANTINO P, GANDINI S, TRAPANI D, et al. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer:a systematic review and meta-analysis of randomized clinical trials[J]. Crit Rev Oncol Hematol, 2021, 159:103223. doi:10.1016/j.critrevonc.2021.103223.
[14]	SPORIKOVA Z, KOUDELAKOVA V, TROJANEC R, et al. Genetic markers in triple-negative breast cancer[J]. Clin Breast Cancer, 2018, 18(5):e841-e850. doi:10.1016/j.clbc.2018.07.023.
[15]	WAKS A G, WINER E P. Breast cancer treatment:a review[J]. JAMA, 2019, 321(3):288-300. doi:10.1001/jama.2018.19323.
[16]	CHAUDHARY L N, WILKINSON K H, KONG A. Triple-negative breast cancer:who should receive neoadjuvant chemotherapy?[J]. Surg Oncol Clin N Am, 2018, 27(1),141-153. doi:10.1016/j.soc.2017.08.004.
[17]	POGGIO F, BRUZZONE M, CEPPI M, et al. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer:a systematic review and meta-analysis[J]. Ann Oncol, 2018, 29(7):1497-1508. doi:10.1093/annonc/mdy127.
[18]	EMENS L A. Immunotherapy in triple-negative breast cancer[J]. Cancer J, 2021, 27(1):59-66. doi:10.1097/PPO.0000000000000497.
[19]	BORRI F, GRANAGLIA A. Pathology of triple negative breast cancer[J]. Semin Cancer Biol, 2021, 72:136-145. doi:10.1016/j.semcancer.2020.06.005.

组别	CR	手术时间/min	术中出血量/mL
对照组	8（20.0）	82.53±8.53	241.63±8.32
观察组	19（47.5）	43.25±6.85	136.52±8.74
χ²或t	6.765^＊＊	22.706^＊＊	55.097^＊＊

组别	CR	手术时间/min	术中出血量/mL
对照组	8（20.0）	82.53±8.53	241.63±8.32
观察组	19（47.5）	43.25±6.85	136.52±8.74
χ²或t	6.765^＊＊	22.706^＊＊	55.097^＊＊

组别	CD4⁺/%					CD8⁺/%
组别	治疗前			治疗后		治疗前		治疗后
对照组	32.42±2.25			34.73±2.32		31.53±2.61		28.94±2.33
观察组	32.65±2.17			38.42±2.85		31.86±2.76		22.86±2.16
t	0.466			6.342^＊＊		0.540		12.115^＊＊
组别		CD4⁺/CD8⁺			IgG/（g/L）
组别		治疗前	治疗后		治疗前		治疗后
对照组		1.19±0.22	1.22±0.32		15.53±1.72		13.52±1.54
观察组		1.23±0.17	1.61±0.35		15.82±3.64		11.57±1.65
t		1.062	5.235^＊＊		0.444		5.439^＊＊
组别		IgA/（g/L）				IgM/（g/L）
组别		治疗前		治疗后		治疗前		治疗后
对照组		2.11±0.38		2.15±0.37		1.85±0.29		1.55±0.23
观察组		2.09±0.43		1.92±0.42		1.88±0.42		1.39±0.27
t		0.221		2.630^＊＊		0.374		2.830^＊＊

组别	CD4⁺/%					CD8⁺/%
组别	治疗前			治疗后		治疗前		治疗后
对照组	32.42±2.25			34.73±2.32		31.53±2.61		28.94±2.33
观察组	32.65±2.17			38.42±2.85		31.86±2.76		22.86±2.16
t	0.466			6.342^＊＊		0.540		12.115^＊＊
组别		CD4⁺/CD8⁺			IgG/（g/L）
组别		治疗前	治疗后		治疗前		治疗后
对照组		1.19±0.22	1.22±0.32		15.53±1.72		13.52±1.54
观察组		1.23±0.17	1.61±0.35		15.82±3.64		11.57±1.65
t		1.062	5.235^＊＊		0.444		5.439^＊＊
组别		IgA/（g/L）				IgM/（g/L）
组别		治疗前		治疗后		治疗前		治疗后
对照组		2.11±0.38		2.15±0.37		1.85±0.29		1.55±0.23
观察组		2.09±0.43		1.92±0.42		1.88±0.42		1.39±0.27
t		0.221		2.630^＊＊		0.374		2.830^＊＊

组别	n	治疗前	治疗后
对照组	40	67.25±5.74	75.93±6.12
观察组	40	67.83±5.82	84.55±6.09
t		0.445	6.319^＊＊